Table 4 Summary of RDI (safety population)a.

From: Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

 

Non-frailb

Frail

 

Fit (19.9%c; n = 145/729)

Intermediate (34.3%c; n = 250/729)

Total–non-frailb (54.2%c; n = 395/729)

Frail (45.8%c; n = 334/729)

 

D-Rd (18.7%d; n = 68/364)

Rd (21.1%e; n = 77/365)

D-Rd (35.2%d; n = 128/364)

Rd (33.4%e; n = 122/365)

D-Rd (53.8%d; n = 196/364)

Rd (54.5%e; n = 199/365)

D-Rd (46.2%d; n = 168/364)

Rd (45.5%e; n = 166/365)

Lenalidomide RDI, %

        

 N

66

75

125

120

191

195

148

153

 Mean (SD)

74.7 (31.8)

79.7 (20.7)

75.9 (29.7)

80.9 (28.6)

75.5 (30.4)

80.4 (25.8)

66.4 (27.8)

85.1 (34.0)

 Median (range)

70.4 (20.9–235.7)

84.7 (24.9–100.0)

79.7 (7.9–241.2)

86.6 (20.6–238.6)

77.2 (7.9–241.2)

86.4 (20.6–238.6)

65.4 (9.5–175.0)

92.9 (4.8–238.1)

Dexamethasone RDI, %

        

 Mean (SD)

73.3 (21.9)

77.6 (21.5)

74.3 (22.4)

81.0 (19.3)

74.0 (22.2)

79.7 (20.2)

80.2 (20.0)

83.3 (21.2)

 Median (range)

71.5 (30.8–100.0)

83.3 (29.9–100.8)

77.5 (22.9–100.0)

85.8 (27.2–100.0)

75.0 (22.9–100.0)

84.8 (27.2–100.8)

85.8 (28.0–110.7)

90.3 (18.9–154.5)

Daratumumab RDI, %

        

 Mean (SD)

97.8 (5.7)

–

96.6 (7.7)

–

97.0 (7.1)

–

94.5 (13.1)

–

 Median (range)

98.4 (61.5–104.7)

–

98.2 (38.5–107.0)

–

98.2 (38.5–107.0)

–

98.0 (3.2–107.0)

–

  1. RDI relative dose intensity, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, SD standard deviation.
  2. aPercentages in the table were calculated using the number of patients in each treatment cohort per frailty subgroup of the safety population (fit: D-Rd, n = 68; Rd, n = 77; intermediate: D-Rd, n = 128;Rd, n = 122; total–non-frail: D-Rd, n = 196; Rd, n = 199; frail: D-Rd, n = 168; Rd, n = 166) as the denominator, unless otherwise indicated.
  3. bNon-frail subgroup consists of fit and intermediate patients.
  4. cPercentage was calculated using the number of patients in the safety population as the denominator.
  5. dPercentage was calculated using the number of patients in the D-Rd cohort of the safety population as the denominator.
  6. ePercentage was calculated using the number of patients in the Rd cohort of the safety population as the denominator.
Back to article page